Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Monovalent RSV Vaccine · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Group 1 RSV/hMPV dose A1 | EXPERIMENTAL | Participants will receive a single IM (Intramuscular) injection on day 1 of the RSV/hMPV vaccines according to their randomization schedule. |
| Group 2 RSV/hMPV dose A2 | EXPERIMENTAL | Participants will receive a single IM injection on day 1 of the RSV/hMPV vaccines according to their randomization schedule. |
| Group 3 RSV/hMPV dose A3 | EXPERIMENTAL | Participants will receive a single IM injection on day 1 of the RSV/hMPV vaccines according to their randomization schedule. |
| Group 4 RSV/hMPV dose B1 | EXPERIMENTAL | Participants will receive a single IM injection on day 1 of the RSV/hMPV vaccines according to their randomization schedule. |
| Group 5 RSV/hMPV dose B2 | EXPERIMENTAL | Participants will receive a single IM injection on day 1 of the RSV/hMPV vaccines according to their randomization schedule. |
| Group 6 RSV/hMPV dose B3 | EXPERIMENTAL | Participants will receive a single IM injection on day 1 of the RSV/hMPV vaccines according to their randomization schedule. |
| Group 7 RSV/hMPV dose C1 | EXPERIMENTAL | Participants will receive a single IM injection on day 1 of the RSV/hMPV vaccines according to their randomization schedule. |
| Group 8 RSV/hMPV dose C2 | EXPERIMENTAL | Participants will receive a single IM injection on day 1 of the RSV/hMPV vaccines according to their randomization schedule. |
| Group 9 RSV/hMPV dose C3 | EXPERIMENTAL | Participants will receive a single IM injection on day 1 of the RSV/hMPV vaccines according to their randomization schedule. |
| Group 10 RSV/hMPV dose 1 | EXPERIMENTAL | Participants will receive a single IM injection on day 1 of the RSV/hMPV vaccines according to their randomization schedule. |
| Group 11 RSV/hMPV dose 2 | EXPERIMENTAL | Participants will receive a single IM injection on day 1 of the RSV/hMPV vaccines according to their randomization schedule. |
| Group 12 RSV/hMPV dose 3 | EXPERIMENTAL | Participants will receive a single IM injection on day 1 of the RSV/hMPV vaccines according to their randomization schedule. |
| Group 13 Monovalent RSV Vaccine | EXPERIMENTAL | Participants will receive a single IM injection on day 1 of a Monovalent (MV) RSV vaccine according to their randomization schedule. |
| Name | Type | Description |
|---|---|---|
| RSV/hMPV vaccine dose A1 | BIOLOGICAL | Suspension for injection. Route of administration: IM injection |
| RSV/hMPV vaccine dose A2 | BIOLOGICAL | Suspension for injection. Route of administration: IM injection |
| RSV/hMPV vaccine dose A3 | BIOLOGICAL | Suspension for injection. Route of administration: IM injection |
| RSV/hMPV vaccine dose B1 | BIOLOGICAL | Suspension for injection. Route of administration: IM injection |
| RSV/hMPV vaccine dose B2 | BIOLOGICAL | Suspension for injection. Route of administration: IM injection |
| RSV/hMPV vaccine dose B3 | BIOLOGICAL | Suspension for injection. Route of administration: IM injection |
| RSV/hMPV vaccine dose C1 | BIOLOGICAL | Suspension for injection. Route of administration: IM injection |
| RSV/hMPV vaccine dose C2 | BIOLOGICAL | Suspension for injection. Route of administration: IM injection |
| RSV/hMPV vaccine dose C3 | BIOLOGICAL | Suspension for injection. Route of administration: IM injection |
| RSV/hMPV vaccine dose 1 | BIOLOGICAL | Suspension for injection. Route of administration: IM injection |
| RSV/hMPV vaccine dose 2 | BIOLOGICAL | Suspension for injection. Route of administration: IM injection |
| RSV/hMPV vaccine dose 3 | BIOLOGICAL | Suspension for injection. Route of administration: IM injection |
| Monovalent RSV Vaccine | BIOLOGICAL | Suspension for injection. Route of administration: IM injection |
Inclusion Criteria: * Aged 60 to 75 years on the day of inclusion * A female participant is eligible to participate if she is post-menopausal for at least 1 year, or surgically sterile Exclusion Criteria: * Any condition which, in the opinion of the Investigator, might interfere with the evaluati...
Top 19 of 30 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
The monovalent RSV vaccine is an investigational vaccine developed by Sanofi (ticker SNY) for the prevention of respiratory syncytial virus infection. It is a vaccine modality in the infectious disease therapeutic area and is currently in Phase 1 clinical development. It is not approved and remains under study.
The monovalent RSV vaccine is being studied for the prevention of RSV infection. Its completed Phase 1 trial also evaluated the vaccine against human metapneumovirus, or hMPV, in adults aged 60 to 75 years. The vaccine is investigational and has not been approved for use.
Sanofi, which trades under the ticker SNY, is the developer of the monovalent RSV vaccine. Sanofi is running the clinical development program for this investigational vaccine candidate against RSV infection.
The monovalent RSV vaccine is in Phase 1 clinical development. One Phase 1 trial has been completed, and no trials are currently active. The vaccine is investigational and has not been approved by the FDA or any other regulatory authority.
The monovalent RSV vaccine has been studied in one completed Phase 1 trial, NCT06583031. That randomized, double-blind, controlled study enrolled 385 healthy volunteers aged 60 to 75 years in Australia and evaluated safety and immune response against RSV and hMPV. No trials are currently active.